Skip to main content
SpringerLink
Log in

Clinical Implications of Burkitt Lymphoma

  • Chapter
  • First Online:
Burkitt’s Lymphoma

Part of the book series: Current Cancer Research ((CUCR))

  • 995 Accesses

Abstract

Patients with Burkitt lymphoma present a unique challenge to clinicians because of the highly aggressive nature of this neoplasm. Three variants of Burkitt lymphoma are recognized: endemic, sporadic, and immunodeficiency-related [1]. While the epidemiology and some clinical characteristics differ among subtypes, the unifying features are rapid tumor cell growth and a propensity to involve extranodal sites. This chapter will focus on the clinical consequences of these biologic features, which frequently present as oncologic emergencies. These aspects of Burkitt lymphoma need to be readily recognized by physicians caring for these patients since delays in providing optimal therapy can result in poor outcome and early mortality.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, et al (2008) WHO classification of tumours of haematopoietic and lymphoid tissues, fourth edition. International Agency for Reserach on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France in 2008

    Google Scholar 

  2. Gertz MA (2010) Managing tumor lysis syndrome in 2010. Leuk Lymphoma 51(2):179–180

    Article  PubMed  Google Scholar 

  3. Howard SC, Jones DP, Pui CH (2011) The tumor lysis syndrome. N Engl J Med 364(19):1844–1854

    Article  PubMed  CAS  Google Scholar 

  4. Magrath IT, Semawere C, Nkwocha J (1974) Causes of death in patients with Burkitt’s lymphoma–the role of supportive care in overall management. East Afr Med J 51(9):623–632

    PubMed  CAS  Google Scholar 

  5. Agha-Razii M, Amyot SL, Pichette V, Cardinal J, Ouimet D, Leblanc M (2000) Continuous veno-venous hemodiafiltration for the treatment of spontaneous tumor lysis syndrome complicated by acute renal failure and severe hyperuricemia. Clin Nephrol 54(1):59–63

    PubMed  CAS  Google Scholar 

  6. Jasek AM, Day HJ (1994) Acute spontaneous tumor lysis syndrome. Am J Hematol 47(2):129–131

    Article  PubMed  CAS  Google Scholar 

  7. Levin M, Cho S (1996) Acute tumor lysis syndrome in high grade lymphoblastic lymphoma after a prolonged episode of fever. Med Pediatr Oncol 26(6):417–418

    Article  PubMed  CAS  Google Scholar 

  8. Riccio B, Mato A, Olson EM, Berns JS, Luger S (2006) Spontaneous tumor lysis syndrome in acute myeloid leukemia: two cases and a review of the literature. Cancer Biol Ther 5(12):1614–1617

    Article  PubMed  CAS  Google Scholar 

  9. Iversen OH, Iversen U, Ziegler JL, Bluming AZ (1974) Cell kinetics in Burkitt lymphoma. Eur J Cancer 10(3):155–163

    Article  PubMed  CAS  Google Scholar 

  10. Ejaz AA, Mu W, Kang DH, Roncal C, Sautin YY, Henderson G et al (2007) Could uric acid have a role in acute renal failure? Clin J Am Soc Nephrol 2(1):16–21

    Article  PubMed  CAS  Google Scholar 

  11. LaRosa C, McMullen L, Bakdash S, Ellis D, Krishnamurti L, Wu HY et al (2007) Acute renal failure from xanthine nephropathy during management of acute leukemia. Pediatr Nephrol (Berlin, Germany) 22(1):132–135

    Article  Google Scholar 

  12. Shimada M, Johnson RJ, May WS Jr, Lingegowda V, Sood P, Nakagawa T et al (2009) A novel role for uric acid in acute kidney injury associated with tumour lysis syndrome. Nephrol Dial Transplant 24(10):2960–2964

    Article  PubMed  CAS  Google Scholar 

  13. Hijiya N, Metzger ML, Pounds S, Schmidt JE, Razzouk BI, Rubnitz JE et al (2005) Severe cardiopulmonary complications consistent with systemic inflammatory response syndrome caused by leukemia cell lysis in childhood acute myelomonocytic or monocytic leukemia. Pediatr Blood Cancer 44(1):63–69

    Article  PubMed  Google Scholar 

  14. Soares M, Feres GA, Salluh JI (2009) Systemic inflammatory response syndrome and multiple organ dysfunction in patients with acute tumor lysis syndrome. Clinics (Sao Paulo, Brazil) 64(5):479–481

    Article  Google Scholar 

  15. Cairo MS, Bishop M (2004) Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 127(1):3–11

    Article  PubMed  Google Scholar 

  16. Hande KR, Garrow GC (1993) Acute tumor lysis syndrome in patients with high-grade non-Hodgkin’s lymphoma. Am J Med 94(2):133–139

    Article  PubMed  CAS  Google Scholar 

  17. Bowman WP, Shuster JJ, Cook B, Griffin T, Behm F, Pullen J et al (1996) Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a pediatric oncology group study. J Clin Oncol 14(4):1252–1261

    PubMed  CAS  Google Scholar 

  18. Cairo MS, Gerrard M, Sposto R, Auperin A, Pinkerton CR, Michon J et al (2007) Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood 109(7):2736–2743

    PubMed  CAS  Google Scholar 

  19. Stapleton FB, Strother DR, Roy S 3rd, Wyatt RJ, McKay CP, Murphy SB (1988) Acute renal failure at onset of therapy for advanced stage Burkitt lymphoma and B cell acute lymphoblastic lymphoma. Pediatrics 82(6):863–869

    PubMed  CAS  Google Scholar 

  20. Wossmann W, Schrappe M, Meyer U, Zimmermann M, Reiter A (2003) Incidence of tumor lysis syndrome in children with advanced stage Burkitt’s lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase. Ann Hematol 82(3):160–165

    PubMed  CAS  Google Scholar 

  21. Coiffier B, Altman A, Pui CH, Younes A, Cairo MS (2008) Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 26(16):2767–2778

    Article  PubMed  CAS  Google Scholar 

  22. Murrell GA, Rapeport WG (1986) Clinical pharmacokinetics of allopurinol. Clin Pharmacokinet 11(5):343–353

    Article  PubMed  CAS  Google Scholar 

  23. Coiffier B, Mounier N, Bologna S, Ferme C, Tilly H, Sonet A et al (2003) Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin’s lymphoma: results of the GRAAL1 (groupe d’etude des lymphomes de l’adulte trial on rasburicase activity in adult lymphoma) study. J Clin Oncol 21(23):4402–4406

    Article  PubMed  CAS  Google Scholar 

  24. Campara M, Shord SS, Haaf CM (2009) Single-dose rasburicase for tumour lysis syndrome in adults: weight-based approach. J Clin Pharm Ther 34(2):207–213

    Article  PubMed  CAS  Google Scholar 

  25. Giraldez M, Puto K (2010) A single, fixed dose of rasburicase (6 mg maximum) for treatment of tumor lysis syndrome in adults. Eur J Haematol 85(2):177–179

    PubMed  Google Scholar 

  26. Liu CY, Sims-McCallum RP, Schiffer CA (2005) A single dose of rasburicase is sufficient for the treatment of hyperuricemia in patients receiving chemotherapy. Leuk Res 29(4):463–465

    Article  PubMed  CAS  Google Scholar 

  27. McDonnell AM, Lenz KL, Frei-Lahr DA, Hayslip J, Hall PD (2006) Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults. Pharmacotherapy 26(6):806–812

    Article  PubMed  CAS  Google Scholar 

  28. Reeves DJ, Bestul DJ (2008) Evaluation of a single fixed dose of rasburicase 7.5 mg for the treatment of hyperuricemia in adults with cancer. Pharmacotherapy 28(6):685–690

    Article  PubMed  CAS  Google Scholar 

  29. Cortes J, Moore JO, Maziarz RT, Wetzler M, Craig M, Matous J et al (2010) Control of plasma uric acid in adults at risk for tumor lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone–results of a multicenter phase III study. J Clin Oncol 28(27):4207–4213

    Article  PubMed  CAS  Google Scholar 

  30. Goldman SC, Holcenberg JS, Finklestein JZ, Hutchinson R, Kreissman S, Johnson FL et al (2001) A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 97(10):2998–3003

    Article  PubMed  CAS  Google Scholar 

  31. Elitek (rasburicase) prescribing information. www.PDR.net (Revised 2010)

    Google Scholar 

  32. Beutler E (1991) Glucose-6-phosphate dehydrogenase deficiency. N Engl J Med 324(3):169–174

    Article  PubMed  CAS  Google Scholar 

  33. Browning LA, Kruse JA (2005) Hemolysis and methemoglobinemia secondary to rasburicase administration. Ann Pharmacother 39(11):1932–1935

    Article  PubMed  Google Scholar 

  34. Cairo MS, Coiffier B, Reiter A, Younes A, TLS Expert Panel (2010) Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol 149(4):578–586

    Article  PubMed  CAS  Google Scholar 

  35. McGowan CE, Saha S, Chu G, Resnick MB, Moss SF (2009) Intestinal necrosis due to sodium polystyrene sulfonate (kayexalate) in sorbitol. South Med J 102(5):493–497

    Article  PubMed  CAS  Google Scholar 

  36. Allon M, Copkney C (1990) Albuterol and insulin for treatment of hyperkalemia in hemodialysis patients. Kidney Int 38(5):869–872

    Article  PubMed  CAS  Google Scholar 

  37. Ferrannini E, Taddei S, Santoro D, Natali A, Boni C, Del Chiaro D et al (1988) Independent stimulation of glucose metabolism and na  +  -K  +  exchange by insulin in the human forearm. Am J Physiol 255(6 Pt 1):E953–E958

    PubMed  CAS  Google Scholar 

  38. Brenner BM (ed) (2008) Brenner and rector’s the kidney, 8th edn. W.B. Saunders Co, Philadelphia

    Google Scholar 

  39. Sood MM, Sood AR, Richardson R (2007) Emergency management and commonly encountered outpatient scenarios in patients with hyperkalemia. Mayo Clin Proc 82(12):1553–1561

    Article  PubMed  Google Scholar 

  40. Tan HK, Bellomo R, M’Pis DA, Ronco C (2001) Phosphatemic control during acute renal failure: intermittent hemodialysis versus continuous hemodiafiltration. Int J Artif Organs 24(4):186–191

    PubMed  CAS  Google Scholar 

  41. Juimo AG, Temdemno AM, Tapko JB, Yomi J, Teyang A, Tagny G et al (1997) Superior vena cava tumoral thrombosis revealing a Burkitt’s lymphoma and a lymphoblastic non-Hodgkin’s lymphoma. A case report. Angiology 48(3):263–268

    Article  PubMed  CAS  Google Scholar 

  42. Ingram L, Rivera GK, Shapiro DN (1990) Superior vena cava syndrome associated with childhood malignancy: analysis of 24 cases. Med Pediatr Oncol 18(6):476–481

    Article  PubMed  CAS  Google Scholar 

  43. Parish JM, Marschke RF Jr, Dines DE, Lee RE (1981) Etiologic considerations in superior vena cava syndrome. Mayo Clin Proc 56(7):407–413

    PubMed  CAS  Google Scholar 

  44. Loeffler JS, Leopold KA, Recht A, Weinstein HJ, Tarbell NJ (1986) Emergency prebiopsy radiation for mediastinal masses: impact on subsequent pathologic diagnosis and outcome. J Clin Oncol 4(5):716–721

    PubMed  CAS  Google Scholar 

  45. Lanciego C, Pangua C, Chacon JI, Velasco J, Boy RC, Viana A et al (2009) Endovascular stenting as the first step in the overall management of malignant superior vena cava syndrome. AJR Am J Roentgenol 193(2):549–558

    Article  PubMed  Google Scholar 

  46. Gupta H, Davidoff AM, Pui CH, Shochat SJ, Sandlund JT (2007) Clinical implications and surgical management of intussusception in pediatric patients with Burkitt lymphoma. J Pediatr Surg 42(6):998–1001, discussion 1001

    Article  PubMed  Google Scholar 

  47. Mantadakis E, Aquino VM, Strand WR, Quigley R (1999) Acute renal failure due to obstruction in Burkitt lymphoma. Pediatr Nephrol (Berlin, Germany) 13(3):237–240

    Article  CAS  Google Scholar 

  48. Castellano I, Hernandez MT, Gomez-Martino JR, Covarsi A, Bergua J, Gonzalez MA (2000) Acute renal failure as presentation of a Burkitt’s lymphoma. Am J Kidney Dis 36(6):E32

    Article  PubMed  CAS  Google Scholar 

  49. Siegel MB, Alexander EA, Weintraub L, Idelson BA (1977) Renal failure in Burkitt’s lymphoma. Clin Nephrol 7(6):279–283

    PubMed  CAS  Google Scholar 

  50. Kaul P, Javangula K (2007) Burkitt lymphoma masquerading as cardiac tamponade. J Cardiothorac Surg 2:30

    Article  PubMed  Google Scholar 

  51. McLean TW, Farber RS, Lewis ZT, Wofford MM, Pettenati MJ, Pranikoff T et al (2007) Diagnosis of Burkitt lymphoma in pediatric patients by thoracentesis. Pediatr Blood Cancer 49(1):90–92

    Article  PubMed  Google Scholar 

  52. Gu Y, Hou YY, Zhang XB, Hu F (2010) Primary central nervous system burkitt lymphoma as concomitant lesions in the third and the left ventricles: a case study and literature review. J Neurooncol 99(2):277–281

    Article  PubMed  Google Scholar 

  53. Valsamis MP, Levine PH, Rapin I, Santorineou M, Shulman K (1976) Primary intracranial Burkitt’s lymphoma in an infant. Cancer 37(3):1500–1507

    Article  PubMed  CAS  Google Scholar 

  54. Balkundi DR, Murray DL, Patterson MJ, Gera R, Scott-Emuakpor A, Kulkarni R (1997) Penicillin-resistant streptococcus mitis as a cause of septicemia with meningitis in febrile neutropenic children. J Pediatr Hematol Oncol 19(1):82–85

    Article  PubMed  CAS  Google Scholar 

  55. Gokbuget N, Hartog CM, Bassan R, Derigs HG, Dombret H, Greil R et al (2011) Liposomal cytarabine is effective and tolerable in the treatment of central nervous system relapse of acute lymphoblastic leukemia and very aggressive lymphoma. Haematologica 96(2):238–244

    Article  PubMed  Google Scholar 

  56. Pui CH, Thiel E (2009) Central nervous system disease in hematologic malignancies: historical perspective and practical applications. Semin Oncol 36(4 Suppl 2):S2–S16

    Article  PubMed  CAS  Google Scholar 

  57. Norin T (1977) Radiation therapy in Burkitt’s lymphoma of the central nervous system. Acta Radiol Ther Phys Biol 16(1):73–80

    PubMed  CAS  Google Scholar 

  58. Dechambenoit G, Piquemal M, Giordano C, Cournil C, Ba Zeze V, Santini JJ (1996) Spinal cord compression resulting from burkitt’s lymphoma in children. Childs Nerv Syst 12(4):210–214

    Article  PubMed  CAS  Google Scholar 

  59. Seymour JF, Gagel RF (1993) Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin’s disease and non-Hodgkin’s lymphomas. Blood 82(5):1383–1394

    PubMed  CAS  Google Scholar 

  60. Spiegel A, Greene M, Magrath I, Balow J, Marx S, Aurbach GD (1978) Hypercalcemia with suppressed parathyroid hormone in Burkitt’s lymphoma. Am J Med 64(4):691–695

    Article  PubMed  CAS  Google Scholar 

  61. Hammond IW, Ferguson JA, Kwong K, Muniz E, Delisle F (2002) Hyponatremia and syndrome of inappropriate anti-diuretic hormone reported with the use of vincristine: an over-representation of Asians? Pharmacoepidemiol Drug Saf 11(3):229–234

    Article  PubMed  CAS  Google Scholar 

  62. Esposito P, Piotti G, Bianzina S, Malul Y, Dal Canton A (2011) The syndrome of inappropriate antidiuresis: pathophysiology, clinical management and new therapeutic options. Nephron Clin Pract 119(1):c62–c73; discussion c73

    Google Scholar 

Download references

Acknowledgements

The authors thank Amanda Gordon, MSN and Elise Chong, MSIII for ­assistance in preparation of this manuscript.

Author information

Authors and Affiliations

  1. Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, 3400 Civic Center Blvd., Philadelphia, PA, 19104, USA

    Jakub Svoboda & Stephen J. Schuster

Authors
  1. Jakub Svoboda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen J. Schuster
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jakub Svoboda .

Editor information

Editors and Affiliations

  1. Perelman School of Medicine, University of Pennsylvania, Hamilton Walk 3610, Philadelphia, 19104, Pennsylvania, USA

    Erle S. Robertson

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer New York

About this chapter

Cite this chapter

Svoboda, J., Schuster, S.J. (2013). Clinical Implications of Burkitt Lymphoma. In: Robertson, E. (eds) Burkitt’s Lymphoma. Current Cancer Research. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-4313-1_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-4313-1_4

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-4312-4

  • Online ISBN: 978-1-4614-4313-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation